Improving PRRT for Neuroendocrine Tumors (NETs) скачать в хорошем качестве

Improving PRRT for Neuroendocrine Tumors (NETs)

The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy called Peptide Receptor Radionuclide Therapy (PRRT) used for the treatment of Neuroendocrine Tumors. In this video, you will meet researchers who are exploring methods that may improve the benefits of PRRT in order to: • Expand the number of patients able to benefit from PRRT • Increase its precision to target even the smallest signs of cancer • Reduce the toxicity of treatments As the major private funder of NET research, NETRF is able to quickly pursue a promising advance in medicine like PRRT to recruit the most talented experts in the world. www.netrf.org CREDITS & THANKS: Animations depicting research performed by the "Targeted Radionuclide Therapy (TRNT)" consortium chaired by Prof Dr. Marion de Jong, Department of Nuclear Medicine, Eramus Medical Centrum and COST programme (www.cost.aukank) under grant BM0607. Animation by Nymus3D Patients and staff at Peter MacCallum Cancer Centre, Australia (www.petermac.org). Supplied by Unicorn Foundation (www.unicornfoundation.org.au)